Short- and long-term neonatal outcomes according to differential exposure to antenatal corticosteroid therapy in preterm births prior to 24 weeks of gestationopen access
- Authors
- Kim, S.-M.[Kim, S.-M.]; Sung, J.-H.[Sung, J.-H.]; Kuk, J.-Y.[Kuk, J.-Y.]; Cha, H.-H.[Cha, H.-H.]; Choi, S.-J.[Choi, S.-J.]; Oh, S.-Y.[Oh, S.-Y.]; Roh, C.-R.[Roh, C.-R.]
- Issue Date
- 4-Jun-2018
- Publisher
- Public Library of Science
- Citation
- PLoS ONE, v.13, no.6
- Indexed
- SCIE
SCOPUS
- Journal Title
- PLoS ONE
- Volume
- 13
- Number
- 6
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/24265
- DOI
- 10.1371/journal.pone.0198471
- ISSN
- 1932-6203
- Abstract
- Aim To assess the effects of differential exposure to antenatal corticosteroid (ACS) on short- and long-term outcomes of infants born before 24 weeks of gestation. Methods This is a retrospective cohort study of 147 infants delivered by 116 women at 21–23 weeks of gestation between January 2001 and December 2016 at a tertiary referral hospital in Seoul, Korea. Eligible subjects were categorized into the following three groups according to ACS exposure: non-user (n = 53), partial-course (n = 44), and complete-course (n = 50). Univariable and multivariable analyses were used to compare neonatal mortality, neonatal morbidities including intraventricular hemorrhage (IVH), and neurodevelopmental impairment including cerebral palsy among the three groups. Results Neonatal mortality rate was significantly lower in the ACS-user groups (non-user, 52.8%; partial-course, 27.3%; complete-course, 28.0%; P = 0.01), but complete-course of ACS therapy had no advantages over partial-course. A lower incidence of IVH was observed in the complete-course group (non-users, 54.8%; partial-course, 48.6%; complete-course, 20.5%; P = 0.003). Multiple logistic regression analysis showed that ACS therapy, either partial- or complete-course, was associated with a lower rate of neonatal mortality (adjusted odds ratio (aOR) 0.375; 95% confidence interval (CI) 0.141–0.996 in partial-course; aOR 0.173; 95% CI 0.052–0.574) in complete-course). IVH (aOR 0.191; 95% CI 0.071–0.516) was less likely to occur in the complete-course group than in the non-user group. Neurodevelopmental impairment of survivors at 18–22 month after birth was not significantly different among the three groups. Conclusion ACS therapy in preterm births at 21–23 weeks of gestation was associated with significantly reduced rates of neonatal mortality and IVH, especially with complete administration. © 2018 Kim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/24265)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.